Res Nova Bio

ResNova Bio is a Houston-based biotechnology company focused on the discovery and development of small molecule inhibitors for high-value, "undruggable" targets in oncology. The company's primary focus is on the KRAS G12D mutation, a frequent driver in pancreatic, colorectal, and lung cancers. ResNova Bio utilizes a proprietary drug discovery platform that combines structural biology and computational chemistry to identify novel binding pockets on oncogenic proteins. Founded in collaboration with researchers from the MD Anderson Cancer Center and supported by Fannin Innovation Studio, the company aims to advance its lead candidate, RN-101, into clinical trials. Their approach emphasizes high selectivity and potency to overcome the limitations of current therapeutic options for solid tumors.